Gastrointestinal Cancers Recap at ASCO 2022: Dr Tanios Bekaii-Saab
June 6th 2022OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Frontline Brentuximab Vedotin Plus Chemotherapy Improves 6-Year Survival in Hodgkin Lymphoma
June 3rd 2022Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine demonstrated a significant reduction in the risk of death vs doxorubicin, bleomycin, vinblastine, and dacarbazine, with a manageable safety profile consistent with prior findings in patients with previously untreated stage III/IV classical Hodgkin lymphoma.
Ovarian Suppression with GnRH Agonists Can Aid Fertility Preservation in Breast Cancer
Treatment regimens that include ovarian suppression with a gonadotropin-releasing hormone agonist have gained momentum in recent years as a potential solution to address treatment-related early menopause for women with breast cancer.
The addition of abemaciclib to endocrine therapy improved invasive disease-free survival and distant relapse-free survival vs endocrine therapy alone in patients with high-risk, hormone receptor–positive, HER2-negative, early-stage breast cancer, irrespective of menopausal status.
Tafasitamab/Lenalidomide Improves OS Over Other Options in Retrospective Relapsed/Refractory DLBCL
The combination of tafasitamab and lenalidomide prolonged median overall survival compared with other standard options for autologous stem cell transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma.
Management Strategies Shift Across NSCLC, Small Cell Lung Cancer, and Mesothelioma
October 7th 2021As novel therapies, new treatment strategies, and ongoing clinical trials continue to steer the path forward in lung cancer, treatment patterns for patients with non–small cell lung cancer, small cell lung cancer, and mesothelioma are continuing to evolve.
Non–CAR T-Based Strategies Shake Up the Management of Non-Hodgkin Lymphoma
August 13th 2021Stephen M. Ansell, MD, PhD, discusses recent progress made with non–CAR T-based approaches in the non-Hodgkin lymphoma treatment paradigm, opportunities for sequencing available options, and ongoing efforts that are picking up momentum.